MDxHealth SA

Thank you for your continued patience.

Your meeting will begin shortly. ¶¶ Thank you.

Thank you for your continued patience. Your meeting will begin shortly.

If you need assistance at any time, please press star zero, and a member of our team will be happy to help you. ¶¶ ¶¶ ¶¶ © transcript Emily Beynon Thank you. Thank you for your continued patience.

Your meeting will begin shortly.

If you need assistance at any time, please press star zero and a member of our team will be happy to help you. ¶¶ © transcript Emily Beynon ¦ ¦ ¦ Please stand by.

Your meeting is about to begin. Good afternoon, everyone, and welcome to today's MDX Health First Quarter 2026 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, you will have the opportunity to ask questions during the question and answer session. To register to ask a question at any time, please press star 1 on your telephone. To remove yourself from the queue, press star 2. Please note, today's call is being recorded and it is now my pleasure to turn the meeting over to Mr. John Francis. Please go ahead, sir.

Before we begin, I would like to remind everyone that the company will make forward-looking statements during today's call. Whether in prepared remarks or during the Q&A session, These forward-looking statements are subject to inherent risks and uncertainties. These risks and uncertainties are detailed in the risk factor section of the company's filings with the Securities and Exchange Commission, specifically in the company's annual report on Form 20F. I'll now turn the call over to Michael McGarrity, Chief Executive Officer.

Thanks, John. And thank you all for joining us for our first quarter 2026 earnings conference call. With me today is Ron Kelfis, Interim Chief Financial Officer. Since I joined MDX Health, we have been very consistent in our message and our mission. We are driven by three core operating principles, focus, execution, and growth. And while our commitment to those principles remains absolute, we also carry a great responsibility to our patients, our customers, and our stakeholders to to make strategic decisions that are rooted in transparency and operating discipline. Our Q1 results, our recent developments, and the disclosures we issued today reflect a number of decisions driven by that exact responsibility. Over the past few years, our aggressive growth strategy and commercial execution have positioned MDX Health as the leader in precision diagnostics focused specifically in urology. This strategy transformed our company from $11 million in revenue in 2019 to $108 million in 2025. We took gross margins from the 20s to the mid-60s, and we reached adjusted EBITDA profitability last year prior to our acquisition of the ExoDx business. However, as we prioritize the ongoing integration of ExoDx and the growth of our core prostate cancer business, we have made the strategic decision to discontinue our resolved UTI offering and to cease operations at our laboratory facility in Plano, Texas. This was a carefully considered decision. The resolved test was uniquely designed for our urology customer base to aid in the rapid diagnosis and treatment of patients presenting with serial complex multi-organism infections. Despite the urgent clinical need and the undeniable medical necessity of this test to the urologist to order it, the increasingly uncertain reimbursement landscape has made the continued operation of this business line unsustainable. Specifically, an unexplained recent policy reversal by our Texas Labs Medicare administrator, Novitas, has created a level of payer uncertainty that we are simply no longer willing to accept. In connection with this, we recently received a communication from Novitas seeking up to $10.4 million in recoupments of historical Resolve testing claims. We believe this action by Novitas is without merit and we are vigorously defending our position through the formal Medicare appeals process. We remain fully confident in our appellate strategy and in the clinical validity of our testing services. While stepping away from Resolve is unfortunate, for the thousands of patients who have benefited from the test. We view this proactive exit as a powerful catalyst for our company. First and foremost, it allows us to focus our capital and operational excellence entirely on our prostate cancer precision diagnostics, where we drive the most scalable value. By stepping away from the reimbursement volatility of Resolve, our entire sales organization is now able to focus 100% on our core prostate cancer menu, Confirm, GPS, and ExoDx. It is important to highlight that we have already completed the ExoDriven strategic mapping and cross-training of our expanded sales force in Q1. Furthermore, We successfully met our internal goal of transitioning our select MDX customers to EXO, resulting in accelerating operating efficiencies as we no longer process select samples. With our sales force fully armed and aligned, we are cementing our position as the growth vertical in urology, offering an unmatched suite of precision diagnostics, addressing every single point in the prostate cancer pathway. An additional value driver of this refocus is our ability to catalyze our commitment to leveraging artificial intelligence. Earlier this year, we initiated an AI dedicated strategic initiative to build out an AI data platform across the company. With the hundreds of thousands of unique biopsy tissue specimens we receive, our goal is to leverage AI to advance operating efficiency, maximize clinical value, and optimize our customer experience. In fact, we are seeing evidence of this with our landmark PROTECT trial in collaboration with the University of Oxford, where the study protocol now includes AI-enhanced endpoints targeted to improve the prognostic value of our GPS test. Furthermore, we have initiated a collaboration with a customer-facing digital innovation company to develop AI-enhanced offerings that build on the evidence-based excellence of our tissue tests. We are incredibly proud of our team's commitment to not only the financials, but to what really matters, the patient and family on the other side of every sample we receive. I will follow up with some closing comments and our updated view forward, but first let me turn the call over to Ron to walk through our first quarter financial results.

Ron?

Thank you, Mike. Before I dive into the financial results, I want to briefly frame our Q1 presentation. Because our Board's strategic decision to exit the Resolve MDX business occurred in April, the financial results of the Plano Laboratory and Resolve business remain embedded within our, as reported, continuing operations for the first quarter. However, To provide investors with a clear and transparent view of our core business trajectory moving forward, we have provided pro forma as adjusted tables in our earnings release. These tables entirely back out the revenue and direct operating expenses of the resolved business. To help you model the ongoing business, I will provide a statutory result today and compare them directly to these pro forma metrics of our continuing prostate cancer operations. Our as-reported revenue for the first quarter ended March 31, 2026, was $27.4 million. However, on a performer basis, excluding the resolved business entirely, revenues for our core prostate cancer operations increased by 11% to $23.9 million, demonstrating the continued commercial execution of our integrated sales team. Moving below the revenue line, our statutory as reported gross profit was $16.6 million. When we back out the resolved business, our pro forma gross profit for the quarter was $15 million, yielding a pro forma gross margin of 62.9% compared to 68% for Q1 2025, with a difference primarily related to tissue versus liquid mix. our as reported operating expenses for the quarter were $23.9 million, resulting in an as reported operating loss of $7.3 million. On a pro forma basis, excluding the direct operating expenses of resolve, our pro forma operating expenses were $22.9 million, resulting in a pro forma operating loss of $7.9 million, compared to a pro forma operating loss of $4.7 million for the prior year, primarily related to the addition of the ExoDX business. Our statutory as reported net loss was $8.9 million. Excluding Resolve, our pro forma net loss was $9.4 million, compared to a pro forma net loss of $9.3 million for Q1 of last year. Once again, I'd like to direct investors to the tables at the back of today's press release, where we have provided a detailed columnar reconciliation of our statutory IFRS results to the pro forma adjustments. Finally, our balance sheet remains solid for the quarter, with cash and cash equivalents as of March 31, 2026, totaling $43.2 million. In addition, on April 15th, we made the 2025 earn-out payment to Exact Sciences in the amount of $15 million. After taking into account this earn-out payment, our pro forma cash as of March 31st, 2026, would have been $28.2 million. This concludes my overview of the financial results, and I will now turn the call back to Mike.

Thanks, Ron. As we look forward, we believe that the near-term impact of our strategic exit from Resolve will ultimately augment our ability to drive sustainable, highly profitable growth across our core prostate cancer menu. By streamlining our operations and removing the reimbursement noise associated with the UTI business, we are effectively resetting our growth trajectory. Today we are establishing updated 2026 revenue guidance for our core cancer business, excluding Resolve, of $110 to $115 million. This represents a robust 20% to 26% year-over-year growth rate for our core cancer business. Our culture of quality first and customer always will ensure our growing reputation for excellence in the urology market. We will continue to strive to deliver on our commitments of growth and value, positioning MDX Health as the leading precision diagnostics company focused solely on the high-growth urology space. As always, we carry a great deal of responsibility to provide value to all of our stakeholders, including our patients, our clinicians, our payers, and our shareholders. Thank you for your continued interest in and support of MDX Health. Now I'll turn the call back to the operator for questions.

Thank you, Mr. McGarrity. Ladies and gentlemen, at this time, if you do have any questions, please press star 1. And as a reminder, you can remove yourself from the queue by pressing star 2. Once again, that's star 1 for questions. We'll go first this afternoon to Dan Brennan with TD Cowan.

Great, guys. Thanks for the questions. Maybe just starting on the Novitas issue, I guess you guys cite the $10.4 million related to retrospective review of certain historical resolve MDX claims. I know you're going to vigorously defend it, but any other call you can provide on what the issue is there and given the cash balance, how do we think about the $10.4 million and just the cushion you guys think you have on that and anything on timing, how this will play out?

Yeah, Dan, we anticipate this will not be resolved or adjudicated for a significant period of time unless it's immediately in our favor. And we feel like that's a high likelihood. We, you know, this is a very recent development that we're communicating. So we, you know, we have no sense of our multiple initial replies. So it's difficult to bracket the timeline. but likely well beyond the period of time that we're focused on here between now and the end of the year. And I would say that although we don't anticipate any liability or recoupment, if there were any minimal, it would be amortized over a five-year period. But I only share that based on our understanding. We don't anticipate we anticipate a quick positive resolution or a longer-term adjudication in our favor.

Got it.

And, Mike, is there any, just maybe one more quick one there, is there any issues or any feedback you've had throughout the process of billing there where they were calling into question, you know, clinical utility of the test, or is there any issues on that front, or just anything else you can share on that front?

If you can imagine, we don't have any further comment on any communication back and forth other than to present full transparency on everything we know as of today. I will say we have absolute certainty and would find impossible to argue the medical necessity and clinical validity of our tests for the patients that are treated. It's important to note that a lot of this focus on fraud and abuse with infectious disease testing, which UTI has been noted in what is not policy-based, but communications coming out of Novotest, it is not the type of test that we are offering to the customer base we are. We market our tests specifically to urology customers for a very specific patient population. And it is patients that are referred to urology, right? When you have a UTI, you don't call a urologist. This is not your run of the mill. Immediate care, get put on Cipro and you're brand new. These are patients that present in men with enlarged prostate or BPH are prone to these. Women are referred to urology for these. We've had patients and clinicians present at our national sales meeting. And the clinical value is impossible to argue, and remarkably compelling. So the broad panel of organisms and susceptibility markers, in addition, a little bit more detail, our test is in the 20s of organisms and susceptibility markers, each run is a specific reaction for each analyte or target organism. So we have exhausted, when we entered the market, or following the AMG guidelines. I'll leave it there, but it leads to our confidence and for sure the medical necessity and our ultimate process.

Got it. No, thanks for that, Mike. Maybe for the follow-up, just on the core, maybe versus your guys' expectations, obviously really strong growth in liquid tissue is up against a really tough comp there. Just give me, how did the quarter play out versus your expectations and as you kind of have the have the updated guide, like kind of what are you incorporating or like how are you thinking about the rest of the year across your two businesses? Thank you.

Thanks, Dan. Yeah, I think we would appreciate your comments because it's what we expected and I communicated as far as Q4 and Q1 with the integration. There will be some focus on the transition of our resolved customers. It's important to note also that every one of our resolved customers is urology customers, so Our reps will be navigating that with our customers. We're confident that we'll navigate through that. And then our guidance adjustment really reflects, while we don't break it out and haven't broken it out historically, maybe the assumption that it's really stripping out our expectation of what Resolve would contribute.

That's essentially the calculus of our new guide.

And any color just on You know, the strength in liquid, obviously, tissue up against really tough comp, but, you know, on a comp-adjusted basis, nice growth. Just, yeah, anything to point out across the two segments, you know, as you look out for the rest of the year?

No, I think there might be some embedded strength there because we, you know, there was some additional adjustment to our Q1 revenue based on the fact that we're conservatively not accruing going forward here, cash only. So I don't have any additional comment other than our guidance clearly reflects confidence in our core cancer business, both tissue and exo. And I'll just add that at the risk of being clever here, we view this as, we believe we'll look back on this as a blessing in disguise from a focus benefit of our sales organization because One rep selling four tests resolved is a great test that has been broadly adopted, but it requires focus and time with our customers and obviously our organizational support of that.

Okay, great. Thanks. Thank you, Dan.

Thank you. We go next now to Bill Bonello with Craig Hallam.

Hey, guys. Thanks for taking the questions. I want to focus a little bit on the cash situation here. So when you think about the restructuring expenses that you're going to incur, do you have any sense of the magnitude of the cash outlay that may go along with that?

Yeah, Bill.

I think we're confident that Our expectation would be the operation would cease by the end of June. Obviously, the majority of the Plano operation is carried in COGS, but we expect to derive any additional expense associated with that will be absorbed by additional efficiencies across our operation that has adjacent or, I guess, blended support of

resolved business in our operation across rcm client services and shared services with operation and product support um so i guess that hopefully that answered your question if i understood your question i mean somewhat i mean it just you know uh you've got you've got i just want to make sure i understand that i mean there's going to be some some severance payments you're going to be making. There's charges on the lease that you mentioned, et cetera. Those are all cash. And so you're thinking you can offset that cash outlay that may come over the next couple of quarters. You can completely offset that with enhancements to the rest of the business?

We're confident that there'll be a considerable offset there, Bill.

Okay.

And then when I think about... The only term I used differently was that completely, I mean, whether it's completely, materially offset.

Yep. Just for transparency purposes. Yep.

Okay. And then just when I look at the pro formas, and I think there's maybe 700 and something thousand dollars of expense that you put with Resolve. Can you give us some sense of what those expenses are? And what I'm trying to get at here is, you know, how easy will it actually be to eliminate operating expense? What's truly attached to Resolve and what was, you know, just, you know, covering fixed costs?

Mainly incentive comp, Bill, through our sales organization for the Resolve test, if I'm understanding that question correctly.

And again, as we... is we're not in a position right now to fully reconcile, but to your two-part question, we expect the majority of the offset of the closing of the operation, the associated costs with that, to be offset by efficiencies across the organization. Then from an OpEx perspective, while I noted that the majority of OpEx, that OpEx will not change materially because the majority of the Plano carry was in COGS, we would expect some benefit. IC is a good example, right?

Okay, that's really helpful. And then just, I guess if I can, and I'll get out of the way and let other people ask questions, but just on the tissue volume, just trying to get a better understanding of what's going on there. It's been you know, sort of moving steadily downward. And I know, you know, you've been doing a big integration and Salesforce was distracted by that. But it's sort of hard to believe at these trends that there's nothing else at all happening. So I guess I'm just trying to get, you know, what can you tell us about whether you're actually been losing some customers on the GPS side or You know, maybe people are, you know, not continuing to use confirm or, you know, why are we seeing volume actually going down?

Yeah, so I think I understand the question. I think I would say there's a multifactorial impact there, right? We have made significant progress, as I've noted, and based on our trending consistent growth profile, is sticky adoption. There are aspects of our tissue-based tests that require focus and continued work with our customer base, with both confirm and GPS. You commented on the integration, which I fully anticipated, and we expect, clearly reflected in our guidance, to see sequential acceleration on the tissue side, even with the focus required on this new development related to Resolve. on the tissue side and q3q I'm sorry q2 q3 and q4 as we go forward and that's part of the calculus that we understand with our our mapping of our customer base our utilization rates are you know the implied churn or whatever that we would have and we've made so much progress on that over the net last couple years and that we're confident that sticks. And, you know, as we look at the comp quarter that Dan noted, we would attribute it to those multiple factors. And our guidance requires that that comes back online on the tissue side as we anticipated at the beginning of the year, knowing that Q1 would be choppy.

Sure. Okay. Thank you. Thank you, Bill.

Thank you. And just a quick reminder, everyone, star one for questions today. We'll go next now to Mark Massaro with BTIG.

Hey, guys. Thank you for taking the question. I apologize. I hopped on the call a few minutes late, so I wanted to just ask a clarifying question. You know, I saw from your press release that you received a Medicare recoupment decision from Novitas, but I wanted to ask, did you receive a non-coverage determination? So I'm just The clarification is, is the coverage suspended at this time?

Mark, my answer to that is we've not, I don't know that Novitas has a coverage policy, which you're very experienced in this segment. I mean, I don't, I think I commented, you know, Moldiac's, Our California MAC has a clear policy related to UTI testing. Novitas does not. There have been communications that have come out over time, probably over the last year or two, where they're calling attention to it and focused on fraud and abuse. I think this is government down. And I think that Moldy X has probably held up as well. Difficult to navigate through Moldy X. We've experienced that. that they have a standard and a policy coverage. We have followed the AMA guidelines and the guidelines associated with how we have built Novitas and Medicare for the past five years, Mark. And we know, I think you would probably know this too from landscape perspective, we know we're not alone here. In fact, I would add an additional point here that we have urology customers that have brought UTI testing in-house through whatever methodology they're using or platform. And they are coming to us saying that they're experiencing reimbursement and they're looking to bring reimbursement challenges and consistencies. But we don't have a policy to lean on to explain their behavior. And we are very confident, to my opening comment, which you missed, we can follow up that medical necessity is unquestioned and a very ambiguous seemingly change in their posture on paying the tests they pay for over time. Okay. Thank you for clarifying that, Mike. We are not willing to try different billing schemes. We're just making what we believe is the prudent near and long-term decision for our for our company and for all of our stakeholders to maintain our transparency and integrity. It's unfortunate. It's remarkably unfortunate because of the value to patients and the way we've responsibly marketed this test.

Okay. So I understand why you made the decision to cease operations in Texas. But, you know, did you guys evaluate the option to run the test out of a separate lab, you know, in a Medicare jurisdiction that does have coverage?

Yeah, Mark, I don't think I'd comment any more on all of the complex decision-making process that we went through. So I don't really have a comment.

I mean, our urban laboratories and Moldiacs, which has a non-coverage decision for a UTI test.

Yeah, all right. And then Last one for me. Are you seeing any, you know, as a follow-up to Bill's question on the tissue volume side, are you seeing any changes in the competitive landscape that you can speak of?

Nothing material from the two competitors on the GPS side. Okay. Thank you for the time. Thank you, Mark. Thank you.

We'll take a follow-up question now from Dan Brennan at TD Cowen.

Hey, guys. Maybe just one more since, you know, we'll probably follow up later. Just, Michael, to your point on the tissue volume acceleration, can you just elaborate a little bit in terms of, you know, some of the initiatives and efforts that you kind of discussed in terms of seeing that sequential acceleration? Any color, qualitative color you can provide? just about the visibility confidence in that acceleration? Thanks.

Yeah, I mean, I think maybe to provide to Mark's last question, you know, the one competitive landscape change I should have noted, Mark, is on the AI side. And I think there's a lot of discussion, I don't want to say noise, but awareness of and communication about the promise of AI in our space, particularly relevant to GPS. And what I noted in our strategy here going forward, including the partnership that we've entered into, is that we've been very patient and rigorous in our processes to the best path forward. We have not been asleep at the wheel, but we've also not panicked. I think we've gone through a prudent exercise of our operational value and use of AI, which does drive, as I noted, all of our clinical data generation and study protocols. But more importantly, the partnership that we've entered into, what I know customer facing, you know, my comment would be there is that this partner provides relevant urology pathology services to our common customer base. So we are very, very confident that our our patient approach there. There's not a company in the space that has been partnered with or available with AI technology that we haven't spoken to, evaluated, and we're very confident that the efforts we're taking internally and the partnership that we have embarked on will drive significant

significant support for our GPS and confirm business.

But that, coupled with our execution focus of the sales organization, I guess those are the couple, two or three different bases that we have for being confident that this issue begins to accelerate as we go forward.

All right. Okay. Thank you. Thank you, Dan.

Thank you. And gentlemen, it appears we have no further questions today. So ladies and gentlemen, that will bring us to the conclusion of today's MDX Health first quarter 2026 earnings conference call. We'd like to thank you all so much for joining us today and wish you all a great rest of your day. Goodbye.